Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PDS Biotechnology: Q3 Earnings Snapshot AP - Thu Nov 14, 7:07AM CST

PDS Biotechnology: Q3 Earnings Snapshot

PDSB : 2.01 (-10.67%)
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results GlobeNewswire - Thu Nov 14, 7:00AM CST

PDSB : 2.01 (-10.67%)
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time GlobeNewswire - Wed Nov 6, 7:00AM CST

PDSB : 2.01 (-10.67%)
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine GlobeNewswire - Tue Oct 22, 7:00AM CDT

PDSB : 2.01 (-10.67%)
PDS Biotechnology: Q2 Earnings Snapshot AP - Tue Aug 13, 7:09AM CDT

PDS Biotechnology: Q2 Earnings Snapshot

PDSB : 2.01 (-10.67%)
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults Newswire.ca - Tue May 28, 12:24PM CDT

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

ONCY : 0.9800 (-2.97%)
TCRX : 4.41 (-8.51%)
BMY : 56.22 (-3.90%)
PDSB : 2.01 (-10.67%)
CCCC : 4.31 (-8.69%)
ONC.TO : 1.38 (-2.13%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates BayStreet.ca - Wed Feb 14, 8:31AM CST

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 0.9800 (-2.97%)
ONC.TO : 1.38 (-2.13%)
TCRX : 4.41 (-8.51%)
BMY : 56.22 (-3.90%)
PDSB : 2.01 (-10.67%)
CCCC : 4.31 (-8.69%)
Wall Street - shutterstock_93231562
S&P Futures Tick Higher Ahead of Key U.S. Inflation Data, U.S. Debt-Ceiling Talks in Focus Barchart - Fri May 26, 2023

June S&P 500 futures (ESM23) are trending up +0.17% this morning after the S&P 500 and Nasdaq 100 closed sharply higher on Thursday as blowout guidance from Nvidia and progress on debt ceiling talks boosted...

ESM23 : 4,453.35s (+0.61%)
NVDA : 141.98 (-3.26%)
RL : 208.38 (-1.46%)
BBY : 92.66 (+1.18%)
INTC : 24.35 (-2.72%)
RIO.LN : 4,807.920 (+1.53%)
GPS : 24.55 (+4.38%)
MRVL : 87.83 (-3.16%)
WDAY : 259.41 (-4.45%)
TLRY : 1.3500 (-2.17%)
PDSB : 2.01 (-10.67%)
MDB : 279.77 (-4.05%)
3 Deeply Undervalued Stocks That Could Double Your Money Motley Fool - Wed Feb 15, 2023

These cutting-edge biotech stocks hold tremendous upside potential.

PDSB : 2.01 (-10.67%)
NTLA : 13.97 (-7.61%)
VERV : 4.79 (-10.97%)
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027 FinancialNewsMedia - Thu Oct 6, 2022

Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...

BIOV.CN : 0.0700 (unch)
BVAXF : 0.0494 (-1.20%)
SGEN : 228.74 (-0.07%)
ZLAB : 27.06 (+1.46%)
PDSB : 2.01 (-10.67%)
ILMN : 135.05 (-5.05%)
GILD : 88.40 (-4.03%)

Barchart Exclusives

Why One Analyst Just Downgraded This Investor-Favorite Energy Dividend Stock Barchart - 2 minutes ago
What’s behind this analyst’s sudden shift to a more cautious stance on Devon Energy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot